Citizens analyst Jason Butler raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $35 from $34 and keeps an Outperform rating on the shares. Acadia’s 2026 guidance is strong, and a key stock driver in 2026 will be remlifanserin results from the Phase 2 trial in Alzheimer’s disease psychosis, the analyst tells investors in a research note. The firm says Acadia is one of its top two picks for the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
- ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
- Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
- Acadia Pharmaceuticals reports Q4 EPS $1.60 vs 86c last year
- Acadia Pharmaceuticals sees FY26 revenue $1.22B-$1.28B, consensus $1.2B